MX2019008436A - Inhibidores del inmunoproteasoma. - Google Patents
Inhibidores del inmunoproteasoma.Info
- Publication number
- MX2019008436A MX2019008436A MX2019008436A MX2019008436A MX2019008436A MX 2019008436 A MX2019008436 A MX 2019008436A MX 2019008436 A MX2019008436 A MX 2019008436A MX 2019008436 A MX2019008436 A MX 2019008436A MX 2019008436 A MX2019008436 A MX 2019008436A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- inhibitors
- immunoproteasoma
- formula
- immunoproteasomes
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
En el presente documento se proporcionan compuestos, tales como un compuesto de fórmula (I), (I) (ver formula) como se describe en el presente documento o una sal farmacéuticamente aceptable de los mismos que son inhibidores del inmunoproteasoma (tal como LMP2 y LMP7). Los compuestos descritos en el presente documento pueden ser útiles para el tratamiento de enfermedades tratables mediante la inhibición de los inmunoproteasomas. También se proporcionan en el presente documento composiciones farmacéuticas que contienen dichos compuestos y procesos para preparar dichos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447717P | 2017-01-18 | 2017-01-18 | |
| US201762508771P | 2017-05-19 | 2017-05-19 | |
| PCT/US2018/013823 WO2018136401A1 (en) | 2017-01-18 | 2018-01-16 | Immunoproteasome inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019008436A true MX2019008436A (es) | 2019-09-18 |
| MX393757B MX393757B (es) | 2025-03-24 |
Family
ID=61906812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008436A MX393757B (es) | 2017-01-18 | 2018-01-16 | Inhibidores del inmunoproteasoma |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11154563B2 (es) |
| EP (1) | EP3571208B1 (es) |
| JP (1) | JP7071400B6 (es) |
| KR (1) | KR102534947B1 (es) |
| CN (1) | CN110248949B (es) |
| AU (1) | AU2018210839B2 (es) |
| CA (1) | CA3049887A1 (es) |
| DK (1) | DK3571208T3 (es) |
| ES (1) | ES2874638T3 (es) |
| HR (1) | HRP20210663T1 (es) |
| HU (1) | HUE054460T2 (es) |
| LT (1) | LT3571208T (es) |
| MX (1) | MX393757B (es) |
| PL (1) | PL3571208T3 (es) |
| PT (1) | PT3571208T (es) |
| RS (1) | RS61811B1 (es) |
| SI (1) | SI3571208T1 (es) |
| TW (1) | TWI821169B (es) |
| UY (1) | UY37569A (es) |
| WO (1) | WO2018136401A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018367515B2 (en) | 2017-11-16 | 2023-04-27 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| PT3710457T (pt) | 2017-11-16 | 2022-10-25 | Principia Biopharma Inc | Inibidores de imunoproteossoma |
| CN113135943A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN116940580A (zh) * | 2021-03-05 | 2023-10-24 | Ａｇｃ株式会社 | 化合物、化合物的制造方法及表面处理剂的制造方法 |
| CN119451969A (zh) * | 2022-06-30 | 2025-02-14 | 普林斯匹亚生物制药公司 | 环状硼酸酯及其用途 |
| TW202521539A (zh) * | 2023-08-01 | 2025-06-01 | 美商普林斯匹亞生物製藥公司 | 製造2-[(3r)-2-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧雜環丁烷-3-基)哌𠯤-1-基]-戊-2-烯腈及其溶劑合物形式之方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4963655A (en) * | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| CN1867572B (zh) * | 2003-08-14 | 2012-03-28 | 赛福伦公司 | 蛋白酶体抑制剂及其使用方法 |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| BRPI0507972A (pt) * | 2004-02-23 | 2007-07-24 | Tufts College | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada |
| EP3157909B1 (en) | 2014-06-20 | 2021-04-07 | Principia Biopharma Inc. | Lmp7 inhibitors |
| BR112017006349A2 (pt) * | 2014-10-01 | 2017-12-12 | Merck Patent Gmbh | derivados de ácido borônico |
| NZ730981A (en) * | 2014-10-01 | 2024-01-26 | Merck Patent Gmbh | Boronic acid derivatives |
| AU2018367515B2 (en) * | 2017-11-16 | 2023-04-27 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| PT3710457T (pt) | 2017-11-16 | 2022-10-25 | Principia Biopharma Inc | Inibidores de imunoproteossoma |
-
2018
- 2018-01-16 ES ES18716009T patent/ES2874638T3/es active Active
- 2018-01-16 SI SI201830282T patent/SI3571208T1/sl unknown
- 2018-01-16 LT LTEP18716009.8T patent/LT3571208T/lt unknown
- 2018-01-16 AU AU2018210839A patent/AU2018210839B2/en active Active
- 2018-01-16 HU HUE18716009A patent/HUE054460T2/hu unknown
- 2018-01-16 CN CN201880006923.4A patent/CN110248949B/zh active Active
- 2018-01-16 KR KR1020197023974A patent/KR102534947B1/ko active Active
- 2018-01-16 EP EP18716009.8A patent/EP3571208B1/en active Active
- 2018-01-16 DK DK18716009.8T patent/DK3571208T3/da active
- 2018-01-16 TW TW107101581A patent/TWI821169B/zh active
- 2018-01-16 WO PCT/US2018/013823 patent/WO2018136401A1/en not_active Ceased
- 2018-01-16 RS RS20210507A patent/RS61811B1/sr unknown
- 2018-01-16 US US16/478,788 patent/US11154563B2/en active Active
- 2018-01-16 JP JP2019559003A patent/JP7071400B6/ja active Active
- 2018-01-16 CA CA3049887A patent/CA3049887A1/en active Pending
- 2018-01-16 MX MX2019008436A patent/MX393757B/es unknown
- 2018-01-16 PT PT187160098T patent/PT3571208T/pt unknown
- 2018-01-16 PL PL18716009T patent/PL3571208T3/pl unknown
- 2018-01-16 HR HRP20210663TT patent/HRP20210663T1/hr unknown
- 2018-01-17 UY UY0001037569A patent/UY37569A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20210663T1 (hr) | 2021-05-28 |
| WO2018136401A1 (en) | 2018-07-26 |
| JP7071400B2 (ja) | 2022-05-18 |
| JP7071400B6 (ja) | 2022-06-07 |
| LT3571208T (lt) | 2021-05-25 |
| KR20190104600A (ko) | 2019-09-10 |
| CA3049887A1 (en) | 2018-07-26 |
| CN110248949B (zh) | 2023-02-17 |
| RS61811B1 (sr) | 2021-06-30 |
| MX393757B (es) | 2025-03-24 |
| CN110248949A (zh) | 2019-09-17 |
| EP3571208B1 (en) | 2021-03-10 |
| US20190336515A1 (en) | 2019-11-07 |
| HUE054460T2 (hu) | 2021-09-28 |
| SI3571208T1 (sl) | 2021-06-30 |
| AU2018210839B2 (en) | 2022-01-20 |
| JP2020506956A (ja) | 2020-03-05 |
| EP3571208A1 (en) | 2019-11-27 |
| AU2018210839A1 (en) | 2019-07-25 |
| TW201831446A (zh) | 2018-09-01 |
| ES2874638T3 (es) | 2021-11-05 |
| UY37569A (es) | 2018-08-31 |
| PL3571208T3 (pl) | 2021-09-20 |
| US11154563B2 (en) | 2021-10-26 |
| PT3571208T (pt) | 2021-04-13 |
| KR102534947B1 (ko) | 2023-05-23 |
| TWI821169B (zh) | 2023-11-11 |
| DK3571208T3 (da) | 2021-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012825A (es) | Inhibidores de inmunoproteasoma. | |
| MX2019008436A (es) | Inhibidores del inmunoproteasoma. | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| MX2019000451A (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| CR20160574A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| MX391440B (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| EA202091169A1 (ru) | Применяемые в качестве ингибиторов iap миметики smac и их применение | |
| MX2020005036A (es) | Inhibidores de inmunoproteasoma. | |
| SV2016005317A (es) | Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos |